Search
perampanel (Fycompa)
DEA class 3.
Indications:
- adjunctive treatment of partial seizures for patients >= 12 years of age
Dosage:
- 8-12 mg (preliminary information, presumably PO QD) (consult package insert)
Adverse effects:
- boxed warning of neuropsychiatric effets
- irritability
- aggression
- anger
- anxiety
- paranoia
- euphoria
- agitation
- mental status changes
- dizziness
- drowsiness
- fatigue
- falls
- upper respiratory tract infection
- weight increase
- vertigo
- ataxia or other gait disturbance
- balance disorder
- blurred vision
- dysarthria
- asthenia
- hypersomnia
Laboratory:
- perampanel in serum/plasma
Mechanism of action:
- non-competitive AMPA receptor antagonist
Interactions
drug adverse effects of anticonvulsants
monitor with anticonvulsants
General
anticonvulsant
receptor antagonist
References
- FDA News Release, Oct. 22, 2012
FDA approves Fycompa to treat seizures
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm325038.htm
- U.S. FDA APPROVES EISAI'S AMPA RECEPTOR ANTAGONIST FYCOMPA
(PERAMPANEL) AS ADJUNCTIVE TREATMENT FOR PARTIAL-ONSET SEIZURES
IN PATIENTS WITH EPILEPSY AGE 12 AND OLDER
http://www.eisai.com/news/news201274.html
- Prescriber's Letter 21(8): 2014
No Detail Document.
(subscription needed) http://www.prescribersletter.com